Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer

• Verfasst von: Song, Yurong [VerfasserIn]
• Verfasst von: Kerr, Travis D. [VerfasserIn]
• Verfasst von: Sanders, Chelsea [VerfasserIn]
• Verfasst von: Dai, Lisheng [VerfasserIn]
• Verfasst von: Baxter, Shaneen S. [VerfasserIn]
• Verfasst von: Somerville, Brandon [VerfasserIn]
• Verfasst von: Baugher, Ryan N. [VerfasserIn]
• Verfasst von: Mellott, Stephanie D. [VerfasserIn]
• Verfasst von: Young, Todd B. [VerfasserIn]
• Verfasst von: Lawhorn, Heidi E. [VerfasserIn]
• Verfasst von: Plona, Teri M. [VerfasserIn]
• Verfasst von: Xu, Bingfang [VerfasserIn]
• Verfasst von: Wei, Lei [VerfasserIn]
• Verfasst von: Hu, Qiang [VerfasserIn]
• Verfasst von: Liu, Song [VerfasserIn]
• Verfasst von: Hutson, Alan [VerfasserIn]
• Verfasst von: Karim, Baktiar [VerfasserIn]
• Verfasst von: Burkett, Sandra [VerfasserIn]
• Verfasst von: Difilippantonio, Simone [VerfasserIn]
• Verfasst von: Pinto, Ligia [VerfasserIn]
• Verfasst von: Gebert, Johannes [VerfasserIn]
• Verfasst von: Kloor, Matthias [VerfasserIn]
• Verfasst von: Lipkin, Steven M. [VerfasserIn]
• Verfasst von: Sei, Shizuko [VerfasserIn]
• Verfasst von: Shoemaker, Robert H. [VerfasserIn]
• Titel: Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
• Verf.angabe: Yurong Song, Travis D. Kerr, Chelsea Sanders, Lisheng Dai, Shaneen S. Baxter, Brandon Somerville, Ryan N. Baugher, Stephanie D. Mellott, Todd B. Young, Heidi E. Lawhorn, Teri M. Plona, Bingfang Xu, Lei Wei, Qiang Hu, Song Liu, Alan Hutson, Baktiar Karim, Sandra Burkett, Simone Difilippantonio, Ligia Pinto, Johannes Gebert, Matthias Kloor, Steven M. Lipkin, Shizuko Sei and Robert H. Shoemaker
• Jahr: 2023
• Umfang: 17 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 09.11.2023
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), Artikel-ID 1223915, Seite 1-17
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2023.1223915
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1869889568

Abstract

BackgroundGenome integrity is essential for the survival of an organism. DNA mismatch repair (MMR) genes (e.g., MLH1, MSH2, MSH6, and PMS2) play a critical role in the DNA damage response pathway for genome integrity maintenance. Germline mutations of MMR genes can lead to Lynch syndrome or constitutional mismatch repair deficiency syndrome, resulting in an increased lifetime risk of developing cancer characterized by high microsatellite instability (MSI-H) and high mutation burden. Although immunotherapy has been approved for MMR-deficient (MMRd) cancer patients, the overall response rate needs to be improved and other management options are needed.MethodsTo better understand the biology of MMRd cancers, elucidate the resistance mechanisms to immune modulation, and develop vaccines and therapeutic testing platforms for this high-risk population, we generated organoids and an orthotopic mouse model from intestine tumors developed in a Msh2-deficient mouse model, and followed with a detailed characterization.ResultsThe organoids were shown to be of epithelial origin with stem cell features, to have a high frameshift mutation frequency with MSI-H and chromosome instability, and intra- and inter-tumor heterogeneity. An orthotopic model using intra-cecal implantation of tumor fragments derived from organoids showed progressive tumor growth, resulting in the development of adenocarcinomas mixed with mucinous features and distant metastasis in liver and lymph node.ConclusionsThe established organoids with characteristics of MSI-H cancers can be used to study MMRd cancer biology. The orthotopic model, with its distant metastasis and expressing frameshift peptides, is suitable for evaluating the efficacy of neoantigen-based vaccines or anticancer drugs in combination with other therapies.